고려제약

014570KOSDAQ의약품 제조업

59.5 / 100

Reference Date: 2026-06-10

Financial Score31.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 19.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Pharmaceutical Co., Ltd. is a leading South Korean manufacturer of over-the-counter and specialty pharmaceuticals, renowned for its cold remedy 'Haben' and treatments for CNS diseases such as epilepsy and Parkinson's. The company's flagship products include CNS medications, which are sold through pharmacies, hospitals, and international exports, while also focusing on R&D for new drugs and health functional foods.

Number of Employees

238people

Average Salary

55.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.42Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

0.43Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE

8.08Industry Average 4.017.0Point

2.0x industry avg (excellent)

Debt Ratio

3.56Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼36.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.0% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Neutral
현대건설, 혹서기 현장 안전관리 강화…휴식 인증 인센티브 도입
현대건설의 온열질환 예방 활동 강화 소식은 관련 산업에 긍정적 영향을 미칠 수 있으나, 고려제약과 직접적인 연관성이 없다.
Neutral
현대건설, 여름철 폭염 대응 강화…'온열질환 제로' 총력
현대건설의 폭염 대응 강화 정책이 고려제약과 직접적인 연관성이 없어 중립적 평가.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,210Won52-week high 4,97552-week low 3,210

1-month return0.0Point

1m -19.95% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral자기주식처분결과보고서2026-05-19
Neutral주요사항보고서(자기주식처분결정)2026-05-18
Neutral분기보고서 (2026.03)2026-05-15